Regenxbio Inc (RGNX)
7.41
-0.46
(-5.84%)
USD |
NASDAQ |
Dec 27, 16:00
7.60
+0.19
(+2.56%)
After-Hours: 20:00
Regenxbio Research and Development Expense (Quarterly): 54.43M for Sept. 30, 2024
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Catalyst Pharmaceuticals Inc | 3.284M |
| Vertex Pharmaceuticals Inc | 875.90M |
| Sarepta Therapeutics Inc | 224.48M |
| Edgewise Therapeutics Inc | 32.22M |
| Entrada Therapeutics Inc | 31.26M |